RxDoctor Payments Data

Mallori Fletcher, NP

Gastroenterology · Baton Rouge, LANPI 1750734356

Payments from drug & device makers

$2,858in general payments, 2019–2025

Across 167 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$264
  • Takeda Pharmaceuticals U.S.A., Inc.$183
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$180
  • Ardelyx, Inc.$178
  • Gilead$148
  • plus $773 from 18 others

What the payments were for

  • Food & beverage$2,858100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,858 in reported general payments places this provider in the 40th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana

Medicare billing

Part B allowed, 2024
$51,323
Medicare patients
378
Services billed
546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide45$45,091
CreonLipase/Protease/Amylase17$30,327
IbsrelaTenapanor Hcl11$19,053
Pantoprazole Sodium656$10,790
ClenpiqSod Picosulf/Mag Ox/Citric Ac57$9,173
Colesevelam Hcl18$5,976
Mesalamine18$5,359
Esomeprazole Magnesium123$4,858
Omeprazole241$4,382
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag32$3,881
Vancomycin Hcl20$2,425
Dicyclomine Hcl146$2,424
Budesonide DrBudesonide24$2,415
Sucralfate25$2,320
Lubiprostone19$2,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,132$75,41862 claims
Ardelyx, Inc.Ibsrela$178$19,05311 claims
Ferring Pharmaceuticals Inc.Clenpiq$52$9,17357 claims
Braintree Laboratories, Inc.Suflave$31$3,88132 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$180$2,16216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 254 gastroenterology providers in Louisiana.

Other gastroenterology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →